IBDEI0H1 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7672,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7672,1,3,0)
 ;;=3^DM Type 2 w/ CKD
 ;;^UTILITY(U,$J,358.3,7672,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,7672,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,7673,0)
 ;;=E11.319^^39^386^24
 ;;^UTILITY(U,$J,358.3,7673,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7673,1,3,0)
 ;;=3^DM Type 2 w/ Retinopathy Unspec w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,7673,1,4,0)
 ;;=4^E11.319
 ;;^UTILITY(U,$J,358.3,7673,2)
 ;;=^5002633
 ;;^UTILITY(U,$J,358.3,7674,0)
 ;;=G40.909^^39^386^76
 ;;^UTILITY(U,$J,358.3,7674,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7674,1,3,0)
 ;;=3^Seizure Disorder NOS
 ;;^UTILITY(U,$J,358.3,7674,1,4,0)
 ;;=4^G40.909
 ;;^UTILITY(U,$J,358.3,7674,2)
 ;;=^5003865
 ;;^UTILITY(U,$J,358.3,7675,0)
 ;;=N52.9^^39^386^30
 ;;^UTILITY(U,$J,358.3,7675,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7675,1,3,0)
 ;;=3^Erectile Dysfuntion,Unspec
 ;;^UTILITY(U,$J,358.3,7675,1,4,0)
 ;;=4^N52.9
 ;;^UTILITY(U,$J,358.3,7675,2)
 ;;=^5015763
 ;;^UTILITY(U,$J,358.3,7676,0)
 ;;=I50.22^^39^386^39
 ;;^UTILITY(U,$J,358.3,7676,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7676,1,3,0)
 ;;=3^Heart Failure,Systolic,Chronic
 ;;^UTILITY(U,$J,358.3,7676,1,4,0)
 ;;=4^I50.22
 ;;^UTILITY(U,$J,358.3,7676,2)
 ;;=^5007241
 ;;^UTILITY(U,$J,358.3,7677,0)
 ;;=I50.32^^39^386^37
 ;;^UTILITY(U,$J,358.3,7677,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7677,1,3,0)
 ;;=3^Heart Failure,Diastolic,Chronic
 ;;^UTILITY(U,$J,358.3,7677,1,4,0)
 ;;=4^I50.32
 ;;^UTILITY(U,$J,358.3,7677,2)
 ;;=^5007245
 ;;^UTILITY(U,$J,358.3,7678,0)
 ;;=I50.42^^39^386^38
 ;;^UTILITY(U,$J,358.3,7678,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7678,1,3,0)
 ;;=3^Heart Failure,Systolic & Diastolic,Chronic
 ;;^UTILITY(U,$J,358.3,7678,1,4,0)
 ;;=4^I50.42
 ;;^UTILITY(U,$J,358.3,7678,2)
 ;;=^5007249
 ;;^UTILITY(U,$J,358.3,7679,0)
 ;;=I13.0^^39^386^32
 ;;^UTILITY(U,$J,358.3,7679,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7679,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,7679,1,4,0)
 ;;=4^I13.0
 ;;^UTILITY(U,$J,358.3,7679,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,7680,0)
 ;;=I13.2^^39^386^33
 ;;^UTILITY(U,$J,358.3,7680,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7680,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Fail w/ Stage 5 Chr Kdny
 ;;^UTILITY(U,$J,358.3,7680,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,7680,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,7681,0)
 ;;=I13.10^^39^386^34
 ;;^UTILITY(U,$J,358.3,7681,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7681,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 1-4 Chr Kdny
 ;;^UTILITY(U,$J,358.3,7681,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,7681,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,7682,0)
 ;;=I13.11^^39^386^35
 ;;^UTILITY(U,$J,358.3,7682,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7682,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Fail w/ Stage 5 Chr Kdny
 ;;^UTILITY(U,$J,358.3,7682,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,7682,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,7683,0)
 ;;=E03.9^^39^386^45
 ;;^UTILITY(U,$J,358.3,7683,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7683,1,3,0)
 ;;=3^Hypothyroidism,Unspec
 ;;^UTILITY(U,$J,358.3,7683,1,4,0)
 ;;=4^E03.9
 ;;^UTILITY(U,$J,358.3,7683,2)
 ;;=^5002476
 ;;^UTILITY(U,$J,358.3,7684,0)
 ;;=C61.^^39^386^49
 ;;^UTILITY(U,$J,358.3,7684,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7684,1,3,0)
 ;;=3^Malig Neopl Prostate
